Targeting the Type I Interferon Pathway in Glomerular Kidney Disease: Rationale and Therapeutic Opportunities

Type I interferons (IFNs) are immunostimulatory molecules that can activate the innate and adaptive immune systems. In cases of immune dysfunction, prolonged activation of the type I IFN pathway has been correlated with kidney tissue damage in a wide range of kidney disorders, such as lupus nephriti...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Kidney international reports 2025-01, Vol.10 (1), p.29-39
Hauptverfasser: Tumlin, James, Rovin, Brad, Anders, Hans-Joachim, Mysler, Eduardo F., Jayne, David R.W., Takeuchi, Tsutomu, Lindholm, Catharina, Weiss, Gudrun, Sorrentino, Alessandro, Woollard, Kevin, Ferrari, Nicola
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 39
container_issue 1
container_start_page 29
container_title Kidney international reports
container_volume 10
creator Tumlin, James
Rovin, Brad
Anders, Hans-Joachim
Mysler, Eduardo F.
Jayne, David R.W.
Takeuchi, Tsutomu
Lindholm, Catharina
Weiss, Gudrun
Sorrentino, Alessandro
Woollard, Kevin
Ferrari, Nicola
description Type I interferons (IFNs) are immunostimulatory molecules that can activate the innate and adaptive immune systems. In cases of immune dysfunction, prolonged activation of the type I IFN pathway has been correlated with kidney tissue damage in a wide range of kidney disorders, such as lupus nephritis (LN) and focal segmental glomerulosclerosis (FSGS). Genetic mutations, such as APOL1 risk variants in conjunction with elevated type I IFN expression, are also associated with higher rates of chronic kidney disease in patients with LN and collapsing FSGS. Long-term activation of the type I IFN pathway can result in chronic inflammation, leading to kidney tissue damage, cell death, and decline in organ function. Thus, therapeutic strategies targeting type I IFN could provide clinical benefits to patients with immune dysregulation who are at risk of developing impaired kidney function. Here, we present a critical review of type I IFN signaling, the consequences of chronically elevated type I IFN expression, and therapeutic strategies targeting type I IFN signaling in the context of kidney disease.
doi_str_mv 10.1016/j.ekir.2024.10.013
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11725820</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S246802492401979X</els_id><sourcerecordid>3155718532</sourcerecordid><originalsourceid>FETCH-LOGICAL-c293t-3cc0caaa6dd064eff59d467ddc93f2d73da2e472aa94ccbda7504c283cc3cbf83</originalsourceid><addsrcrecordid>eNp9kc1uEzEUhS0EolXpC7BAXrJJ6p-Z8QxCQqjQElGpCIW1dWPfSRwm9mB7ivI2PAtPhqOUqmxY2Tr3nGPrfoS85GzOGW8utnP87uJcMFEVYc64fEJORdW0s6J0Tx_dT8h5SlvGGFdN3bH2OTmRXcuZUuqU-CXENWbn1zRvkC73I9IFXfiMsccYPP0CefMT9tR5ej2EHcZpgEg_O-txTz-4hJDwDf0K2QUPA_7-Bd7S5QYjjDhlZ-jtOIaYJ--yw_SCPOthSHh-f56Rb1cfl5efZje314vL9zczIzqZZ9IYZgCgsZY1FfZ93dmqUdaaTvbCKmlBYKUEQFcZs7KgalYZ0ZacNKu-lWfk3bF3nFY7tAZ9jjDoMbodxL0O4PS_E-82eh3uNOdK1K1gpeH1fUMMPyZMWe9cMjgM4DFMSUte14q3tRTFKo5WE0NKEfuHdzjTB1h6qw-w9AHWQSuwSujV4x8-RP6iKYa3RwOWPd05jDoZh96gdRFN1ja4__X_AfzIqms</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3155718532</pqid></control><display><type>article</type><title>Targeting the Type I Interferon Pathway in Glomerular Kidney Disease: Rationale and Therapeutic Opportunities</title><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Tumlin, James ; Rovin, Brad ; Anders, Hans-Joachim ; Mysler, Eduardo F. ; Jayne, David R.W. ; Takeuchi, Tsutomu ; Lindholm, Catharina ; Weiss, Gudrun ; Sorrentino, Alessandro ; Woollard, Kevin ; Ferrari, Nicola</creator><creatorcontrib>Tumlin, James ; Rovin, Brad ; Anders, Hans-Joachim ; Mysler, Eduardo F. ; Jayne, David R.W. ; Takeuchi, Tsutomu ; Lindholm, Catharina ; Weiss, Gudrun ; Sorrentino, Alessandro ; Woollard, Kevin ; Ferrari, Nicola</creatorcontrib><description>Type I interferons (IFNs) are immunostimulatory molecules that can activate the innate and adaptive immune systems. In cases of immune dysfunction, prolonged activation of the type I IFN pathway has been correlated with kidney tissue damage in a wide range of kidney disorders, such as lupus nephritis (LN) and focal segmental glomerulosclerosis (FSGS). Genetic mutations, such as APOL1 risk variants in conjunction with elevated type I IFN expression, are also associated with higher rates of chronic kidney disease in patients with LN and collapsing FSGS. Long-term activation of the type I IFN pathway can result in chronic inflammation, leading to kidney tissue damage, cell death, and decline in organ function. Thus, therapeutic strategies targeting type I IFN could provide clinical benefits to patients with immune dysregulation who are at risk of developing impaired kidney function. Here, we present a critical review of type I IFN signaling, the consequences of chronically elevated type I IFN expression, and therapeutic strategies targeting type I IFN signaling in the context of kidney disease.</description><identifier>ISSN: 2468-0249</identifier><identifier>EISSN: 2468-0249</identifier><identifier>DOI: 10.1016/j.ekir.2024.10.013</identifier><identifier>PMID: 39810777</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>anifrolumab ; immune dysfunction ; interferon pathway ; kidney disease ; lupus nephritis ; Review ; type I interferon</subject><ispartof>Kidney international reports, 2025-01, Vol.10 (1), p.29-39</ispartof><rights>2024 International Society of Nephrology</rights><rights>2024 International Society of Nephrology. Published by Elsevier Inc.</rights><rights>2024 International Society of Nephrology. Published by Elsevier Inc. 2024 International Society of Nephrology</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c293t-3cc0caaa6dd064eff59d467ddc93f2d73da2e472aa94ccbda7504c283cc3cbf83</cites><orcidid>0000-0001-5639-0210</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11725820/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11725820/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39810777$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tumlin, James</creatorcontrib><creatorcontrib>Rovin, Brad</creatorcontrib><creatorcontrib>Anders, Hans-Joachim</creatorcontrib><creatorcontrib>Mysler, Eduardo F.</creatorcontrib><creatorcontrib>Jayne, David R.W.</creatorcontrib><creatorcontrib>Takeuchi, Tsutomu</creatorcontrib><creatorcontrib>Lindholm, Catharina</creatorcontrib><creatorcontrib>Weiss, Gudrun</creatorcontrib><creatorcontrib>Sorrentino, Alessandro</creatorcontrib><creatorcontrib>Woollard, Kevin</creatorcontrib><creatorcontrib>Ferrari, Nicola</creatorcontrib><title>Targeting the Type I Interferon Pathway in Glomerular Kidney Disease: Rationale and Therapeutic Opportunities</title><title>Kidney international reports</title><addtitle>Kidney Int Rep</addtitle><description>Type I interferons (IFNs) are immunostimulatory molecules that can activate the innate and adaptive immune systems. In cases of immune dysfunction, prolonged activation of the type I IFN pathway has been correlated with kidney tissue damage in a wide range of kidney disorders, such as lupus nephritis (LN) and focal segmental glomerulosclerosis (FSGS). Genetic mutations, such as APOL1 risk variants in conjunction with elevated type I IFN expression, are also associated with higher rates of chronic kidney disease in patients with LN and collapsing FSGS. Long-term activation of the type I IFN pathway can result in chronic inflammation, leading to kidney tissue damage, cell death, and decline in organ function. Thus, therapeutic strategies targeting type I IFN could provide clinical benefits to patients with immune dysregulation who are at risk of developing impaired kidney function. Here, we present a critical review of type I IFN signaling, the consequences of chronically elevated type I IFN expression, and therapeutic strategies targeting type I IFN signaling in the context of kidney disease.</description><subject>anifrolumab</subject><subject>immune dysfunction</subject><subject>interferon pathway</subject><subject>kidney disease</subject><subject>lupus nephritis</subject><subject>Review</subject><subject>type I interferon</subject><issn>2468-0249</issn><issn>2468-0249</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2025</creationdate><recordtype>article</recordtype><recordid>eNp9kc1uEzEUhS0EolXpC7BAXrJJ6p-Z8QxCQqjQElGpCIW1dWPfSRwm9mB7ivI2PAtPhqOUqmxY2Tr3nGPrfoS85GzOGW8utnP87uJcMFEVYc64fEJORdW0s6J0Tx_dT8h5SlvGGFdN3bH2OTmRXcuZUuqU-CXENWbn1zRvkC73I9IFXfiMsccYPP0CefMT9tR5ej2EHcZpgEg_O-txTz-4hJDwDf0K2QUPA_7-Bd7S5QYjjDhlZ-jtOIaYJ--yw_SCPOthSHh-f56Rb1cfl5efZje314vL9zczIzqZZ9IYZgCgsZY1FfZ93dmqUdaaTvbCKmlBYKUEQFcZs7KgalYZ0ZacNKu-lWfk3bF3nFY7tAZ9jjDoMbodxL0O4PS_E-82eh3uNOdK1K1gpeH1fUMMPyZMWe9cMjgM4DFMSUte14q3tRTFKo5WE0NKEfuHdzjTB1h6qw-w9AHWQSuwSujV4x8-RP6iKYa3RwOWPd05jDoZh96gdRFN1ja4__X_AfzIqms</recordid><startdate>20250101</startdate><enddate>20250101</enddate><creator>Tumlin, James</creator><creator>Rovin, Brad</creator><creator>Anders, Hans-Joachim</creator><creator>Mysler, Eduardo F.</creator><creator>Jayne, David R.W.</creator><creator>Takeuchi, Tsutomu</creator><creator>Lindholm, Catharina</creator><creator>Weiss, Gudrun</creator><creator>Sorrentino, Alessandro</creator><creator>Woollard, Kevin</creator><creator>Ferrari, Nicola</creator><general>Elsevier Inc</general><general>Elsevier</general><scope>6I.</scope><scope>AAFTH</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-5639-0210</orcidid></search><sort><creationdate>20250101</creationdate><title>Targeting the Type I Interferon Pathway in Glomerular Kidney Disease: Rationale and Therapeutic Opportunities</title><author>Tumlin, James ; Rovin, Brad ; Anders, Hans-Joachim ; Mysler, Eduardo F. ; Jayne, David R.W. ; Takeuchi, Tsutomu ; Lindholm, Catharina ; Weiss, Gudrun ; Sorrentino, Alessandro ; Woollard, Kevin ; Ferrari, Nicola</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c293t-3cc0caaa6dd064eff59d467ddc93f2d73da2e472aa94ccbda7504c283cc3cbf83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2025</creationdate><topic>anifrolumab</topic><topic>immune dysfunction</topic><topic>interferon pathway</topic><topic>kidney disease</topic><topic>lupus nephritis</topic><topic>Review</topic><topic>type I interferon</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tumlin, James</creatorcontrib><creatorcontrib>Rovin, Brad</creatorcontrib><creatorcontrib>Anders, Hans-Joachim</creatorcontrib><creatorcontrib>Mysler, Eduardo F.</creatorcontrib><creatorcontrib>Jayne, David R.W.</creatorcontrib><creatorcontrib>Takeuchi, Tsutomu</creatorcontrib><creatorcontrib>Lindholm, Catharina</creatorcontrib><creatorcontrib>Weiss, Gudrun</creatorcontrib><creatorcontrib>Sorrentino, Alessandro</creatorcontrib><creatorcontrib>Woollard, Kevin</creatorcontrib><creatorcontrib>Ferrari, Nicola</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Kidney international reports</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tumlin, James</au><au>Rovin, Brad</au><au>Anders, Hans-Joachim</au><au>Mysler, Eduardo F.</au><au>Jayne, David R.W.</au><au>Takeuchi, Tsutomu</au><au>Lindholm, Catharina</au><au>Weiss, Gudrun</au><au>Sorrentino, Alessandro</au><au>Woollard, Kevin</au><au>Ferrari, Nicola</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Targeting the Type I Interferon Pathway in Glomerular Kidney Disease: Rationale and Therapeutic Opportunities</atitle><jtitle>Kidney international reports</jtitle><addtitle>Kidney Int Rep</addtitle><date>2025-01-01</date><risdate>2025</risdate><volume>10</volume><issue>1</issue><spage>29</spage><epage>39</epage><pages>29-39</pages><issn>2468-0249</issn><eissn>2468-0249</eissn><abstract>Type I interferons (IFNs) are immunostimulatory molecules that can activate the innate and adaptive immune systems. In cases of immune dysfunction, prolonged activation of the type I IFN pathway has been correlated with kidney tissue damage in a wide range of kidney disorders, such as lupus nephritis (LN) and focal segmental glomerulosclerosis (FSGS). Genetic mutations, such as APOL1 risk variants in conjunction with elevated type I IFN expression, are also associated with higher rates of chronic kidney disease in patients with LN and collapsing FSGS. Long-term activation of the type I IFN pathway can result in chronic inflammation, leading to kidney tissue damage, cell death, and decline in organ function. Thus, therapeutic strategies targeting type I IFN could provide clinical benefits to patients with immune dysregulation who are at risk of developing impaired kidney function. Here, we present a critical review of type I IFN signaling, the consequences of chronically elevated type I IFN expression, and therapeutic strategies targeting type I IFN signaling in the context of kidney disease.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>39810777</pmid><doi>10.1016/j.ekir.2024.10.013</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0001-5639-0210</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2468-0249
ispartof Kidney international reports, 2025-01, Vol.10 (1), p.29-39
issn 2468-0249
2468-0249
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11725820
source EZB-FREE-00999 freely available EZB journals; PubMed Central; Alma/SFX Local Collection
subjects anifrolumab
immune dysfunction
interferon pathway
kidney disease
lupus nephritis
Review
type I interferon
title Targeting the Type I Interferon Pathway in Glomerular Kidney Disease: Rationale and Therapeutic Opportunities
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-15T16%3A15%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Targeting%20the%20Type%20I%20Interferon%20Pathway%20in%20Glomerular%20Kidney%20Disease:%20Rationale%C2%A0and%20Therapeutic%20Opportunities&rft.jtitle=Kidney%20international%20reports&rft.au=Tumlin,%20James&rft.date=2025-01-01&rft.volume=10&rft.issue=1&rft.spage=29&rft.epage=39&rft.pages=29-39&rft.issn=2468-0249&rft.eissn=2468-0249&rft_id=info:doi/10.1016/j.ekir.2024.10.013&rft_dat=%3Cproquest_pubme%3E3155718532%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3155718532&rft_id=info:pmid/39810777&rft_els_id=S246802492401979X&rfr_iscdi=true